BE2014C017I2 - - Google Patents

Info

Publication number
BE2014C017I2
BE2014C017I2 BE2014C017C BE2014C017C BE2014C017I2 BE 2014C017 I2 BE2014C017 I2 BE 2014C017I2 BE 2014C017 C BE2014C017 C BE 2014C017C BE 2014C017 C BE2014C017 C BE 2014C017C BE 2014C017 I2 BE2014C017 I2 BE 2014C017I2
Authority
BE
Belgium
Application number
BE2014C017C
Other languages
French (fr)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15924444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BE2014C017I2 publication Critical patent/BE2014C017I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2014C017C 1999-06-17 2014-03-04 BE2014C017I2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17150999 1999-06-17

Publications (1)

Publication Number Publication Date
BE2014C017I2 true BE2014C017I2 (tr) 2019-05-21

Family

ID=15924444

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C017C BE2014C017I2 (tr) 1999-06-17 2014-03-04

Country Status (27)

Country Link
US (11) US6462058B1 (tr)
EP (3) EP2343289A1 (tr)
KR (3) KR100537029B1 (tr)
CN (1) CN1150186C (tr)
AR (5) AR031069A1 (tr)
AT (1) ATE391126T1 (tr)
AU (1) AU778820B2 (tr)
BE (1) BE2014C017I2 (tr)
BR (1) BRPI0011674B8 (tr)
CA (1) CA2375201C (tr)
CY (2) CY1110384T1 (tr)
DE (1) DE60038481T2 (tr)
DK (2) DK1129088T3 (tr)
ES (2) ES2426985T3 (tr)
HK (2) HK1038227A1 (tr)
HU (1) HU229067B1 (tr)
IL (2) IL145996A0 (tr)
MX (1) MXPA01012642A (tr)
MY (1) MY125399A (tr)
NO (1) NO321168B1 (tr)
NZ (1) NZ515702A (tr)
PL (1) PL201068B1 (tr)
PT (2) PT1129088E (tr)
SI (1) SI1129088T1 (tr)
TW (2) TWI275587B (tr)
WO (2) WO2004083200A1 (tr)
ZA (1) ZA200108331B (tr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6608092B1 (en) * 1999-06-30 2003-08-19 Takeda Chemical Industries, Ltd. Crystals of benzimidazole compounds
CN1193024C (zh) 2000-04-28 2005-03-16 武田药品工业株式会社 生产旋光的亚砜衍生物的方法
DK1293507T3 (da) * 2000-05-15 2007-12-27 Takeda Pharmaceutical Fremgangsmåde til fremstilling af krystaller
CA2775616C (en) * 2000-08-04 2013-09-17 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
AU2002218506A1 (en) * 2000-12-01 2002-06-11 Takeda Chemical Industries Ltd. Process for the crystallization of (r)- or (s)-lansoprazole
ES2426723T3 (es) 2001-10-17 2013-10-24 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
KR100467100B1 (ko) * 2002-03-20 2005-01-24 일양약품주식회사 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1Ｈ-피롤-1-릴)-1Ｈ-벤즈이미다졸 또는 이의 Ｎа염을 함유하는주사제의 제조방법
WO2003082857A2 (en) * 2002-03-27 2003-10-09 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP2596791B1 (en) * 2002-10-16 2015-04-01 Takeda Pharmaceutical Company Limited Stable solid preparations
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
DE602004032524D1 (de) * 2003-03-24 2011-06-16 Eisai R&D Man Co Ltd Verfahren zur herstellung von amorphem rabeprazole-natrium-salz
US20070101907A1 (en) * 2003-06-20 2007-05-10 Ch Chemical (Pty) Ltd. Liner
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
EP1742630A4 (en) * 2004-04-16 2010-01-20 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND PROKINETIC AGENT
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
ES2441970T3 (es) 2004-09-13 2014-02-07 Takeda Pharmaceutical Company Limited Método para producir lansoprazol
CA2599340C (en) 2005-02-25 2012-12-04 Takeda Pharmaceutical Company Limited Method for producing granules
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
BRPI0617987A2 (pt) * 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
KR20080081071A (ko) 2005-12-28 2008-09-05 다케다 야쿠힌 고교 가부시키가이샤 방출 제어 고형 제제
KR100758600B1 (ko) 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008068767A2 (en) * 2006-12-07 2008-06-12 Hetero Drugs Limited A novel crystalline form of lansoprazole
EP2098250B1 (en) 2006-12-28 2016-09-28 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
WO2009049160A1 (en) * 2007-10-12 2009-04-16 Takeda Pharmaceuticals North America Methods of treating gastrointestinal disorders independent of the intake of food
BRPI0821386A2 (pt) * 2007-12-18 2015-06-16 Watson Pharma Private Ltd Processo para a preparação de r-lansoprazol amorfo estável
EP2227462A1 (en) * 2007-12-31 2010-09-15 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r) -2- [[[3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl]methyl]sulfinyl]-1h-benz imidazole
CA2671369C (en) 2008-03-10 2011-05-10 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
MY173730A (en) * 2008-03-11 2020-02-18 Takeda Pharmaceuticals Co Orally-disintegrating solid preparation
EP2265605A4 (en) * 2008-03-18 2011-08-03 Reddys Lab Ltd Dr METHOD OF MANUFACTURING DEXLANSOPRAZOLE AND POLYMORPHIDE THEREOF
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
AU2009336561A1 (en) 2008-05-14 2010-07-15 Watson Pharma Private Limited Stable R-(+)-lansoprazole amine salt and a process for preparing the same
ES2660962T3 (es) * 2008-07-28 2018-03-26 Takeda Pharmaceutical Company Limited Composición farmacéutica fotoestabilizada
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
IT1391758B1 (it) * 2008-11-11 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo amorfo
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
IT1392813B1 (it) * 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
US9271986B2 (en) 2009-11-12 2016-03-01 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CN102108076B (zh) * 2009-12-23 2014-07-23 江苏豪森医药集团有限公司 制备无定形右兰索拉唑的方法
AU2011210328A1 (en) 2010-01-29 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
CA2795110C (en) 2010-03-31 2015-06-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
AU2011234001B2 (en) 2010-03-31 2014-08-28 Sun Pharmaceutical Industries Limited Salts of dexlansoprazole and their preparation
EP2384747A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Oral Tablet Compositions Of Dexlansoprazole
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
EP2384745A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of dexlansoprazole
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
MX2013006247A (es) 2010-12-03 2014-01-31 Takeda Pharmaceutical Tableta oralmente desintegradora.
AU2011350396A1 (en) 2010-12-27 2013-07-11 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
WO2012095859A1 (en) * 2011-01-12 2012-07-19 Hetero Research Foundation Polymorphs of dexlansoprazole salts
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
US20140357870A1 (en) * 2011-06-21 2014-12-04 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102875531B (zh) * 2011-07-15 2015-08-19 上海睿智化学研究有限公司 一种(r)-兰索拉唑无水晶型及其制备方法
CN102875530A (zh) * 2011-07-15 2013-01-16 上海睿智化学研究有限公司 一种(r)-兰索拉唑叔丁胺盐及其晶型和制备方法
CN102875532B (zh) * 2011-07-15 2015-05-13 上海睿智化学研究有限公司 一种(r)-兰索拉唑异丙胺盐及其晶型和制备方法
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
US9433632B2 (en) 2011-11-30 2016-09-06 Takeda Pharmaceutical Company Limited Dry coated tablet
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CN103709139B (zh) * 2012-10-09 2016-12-21 上海汇伦生命科技有限公司 无水右兰索拉唑的制备方法
CN104177333A (zh) * 2013-05-24 2014-12-03 四川海思科制药有限公司 一种理化性质稳定的(r)-2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1h-苯并咪唑
CN104650035A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 右兰索拉唑倍半水合物化合物
CN103664889B (zh) * 2013-12-19 2014-11-19 悦康药业集团有限公司 一种兰索拉唑化合物
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
CN104844576B (zh) * 2015-04-28 2017-03-08 山东罗欣药业集团股份有限公司 一种兰索拉唑或右旋兰索拉唑晶型化合物及其制备方法
CN104829594A (zh) * 2015-05-15 2015-08-12 苗怡文 一种治疗胃溃疡的药物兰索拉唑化合物
CN105017218A (zh) * 2015-07-01 2015-11-04 合肥安德生制药有限公司 一种右兰索拉唑晶型及其制备方法
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997738A (zh) * 2015-08-10 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物兰索拉唑组合物干混悬剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN108164507A (zh) * 2016-12-07 2018-06-15 天津药物研究院有限公司 一种右兰索拉唑单晶及其制备方法和用途
TR201701461A2 (tr) 2017-01-31 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dekslansoprazolün Enterik Kaplı Farmasötik Kompozisyonları
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN107011329A (zh) * 2017-05-05 2017-08-04 广州大光制药有限公司 兰索拉唑一水合物晶型及其结晶制备方法
CN108794450B (zh) * 2018-07-24 2022-08-19 浙江恒康药业股份有限公司 制备无定型右旋兰索拉唑的方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6043263A (en) 1996-11-12 2000-03-28 Byk Gulden Lomberg Chemische Fabrik Gmbh (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
CA2271381A1 (en) * 1996-11-22 1998-05-28 Owen Rickford Carryl Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
AU2481899A (en) 1998-01-30 1999-08-16 Sepracor, Inc. S-lansoprazole compositions and methods
WO1999038513A1 (en) 1998-01-30 1999-08-05 Sepracor Inc. R-lansoprazole compositions and methods
WO1999056698A2 (en) * 1998-05-06 1999-11-11 Københavns Universitet Treatment of celiac disease
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
US6608092B1 (en) * 1999-06-30 2003-08-19 Takeda Chemical Industries, Ltd. Crystals of benzimidazole compounds
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法
EP2596791B1 (en) * 2002-10-16 2015-04-01 Takeda Pharmaceutical Company Limited Stable solid preparations
DE602004032524D1 (de) * 2003-03-24 2011-06-16 Eisai R&D Man Co Ltd Verfahren zur herstellung von amorphem rabeprazole-natrium-salz
CA2591983A1 (en) * 2004-12-20 2006-06-29 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising amorphous benzimidazole compounds
EP1830823A2 (en) * 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
BRPI0821386A2 (pt) * 2007-12-18 2015-06-16 Watson Pharma Private Ltd Processo para a preparação de r-lansoprazol amorfo estável

Also Published As

Publication number Publication date
US7569697B2 (en) 2009-08-04
DE60038481D1 (de) 2008-05-15
US20120316344A1 (en) 2012-12-13
US6939971B2 (en) 2005-09-06
WO2004083200A1 (en) 2004-09-30
ATE391126T1 (de) 2008-04-15
WO2000078745A2 (en) 2000-12-28
ES2300265T3 (es) 2008-06-16
TWI275587B (en) 2007-03-11
ES2426985T3 (es) 2013-10-28
NO321168B1 (no) 2006-03-27
EP1129088B1 (en) 2008-04-02
KR20010052467A (ko) 2001-06-25
US8030333B2 (en) 2011-10-04
CY1114485T1 (el) 2017-01-25
CN1150186C (zh) 2004-05-19
US8884019B2 (en) 2014-11-11
PT1977751E (pt) 2013-08-01
US6462058B1 (en) 2002-10-08
EP2343289A1 (en) 2011-07-13
AU5247800A (en) 2001-01-09
BR0011674A (pt) 2002-03-19
HK1123985A1 (en) 2009-07-03
US6664276B2 (en) 2003-12-16
PL201068B1 (pl) 2009-03-31
US20140012006A1 (en) 2014-01-09
WO2000078745A3 (en) 2001-07-05
DE60038481T2 (de) 2009-04-09
US20100222391A1 (en) 2010-09-02
US20110319450A1 (en) 2011-12-29
US8552198B2 (en) 2013-10-08
EP1129088A2 (en) 2001-09-05
DK1129088T3 (da) 2008-06-09
MY125399A (en) 2006-07-31
US7737282B2 (en) 2010-06-15
NO20016087L (no) 2001-12-13
PL352193A1 (en) 2003-08-11
AR079473A2 (es) 2012-01-25
US20150025115A1 (en) 2015-01-22
KR100537029B1 (ko) 2005-12-16
BRPI0011674B1 (pt) 2017-05-30
CA2375201A1 (en) 2000-12-28
NZ515702A (en) 2003-07-25
AU778820B2 (en) 2004-12-23
HUP0201659A2 (hu) 2002-11-28
TWI289557B (en) 2007-11-11
AR031069A1 (es) 2003-09-10
KR100514204B1 (ko) 2005-09-13
BRPI0011674B8 (pt) 2021-05-25
AR103295A2 (es) 2017-05-03
CA2375201C (en) 2010-02-09
AR093609A2 (es) 2015-06-10
US9145389B2 (en) 2015-09-29
HK1038227A1 (en) 2002-03-08
SI1129088T1 (sl) 2008-08-31
HUP0201659A3 (en) 2003-11-28
US20050228026A1 (en) 2005-10-13
HU229067B1 (en) 2013-07-29
CY1110384T1 (el) 2015-04-29
ZA200108331B (en) 2002-10-10
KR20010071354A (ko) 2001-07-28
US7339064B2 (en) 2008-03-04
KR100407847B1 (ko) 2003-12-01
AR100473A2 (es) 2016-10-12
KR20030068592A (ko) 2003-08-21
US20040048898A1 (en) 2004-03-11
EP1977751A1 (en) 2008-10-08
PT1129088E (pt) 2008-05-05
NO20016087D0 (no) 2001-12-13
EP1977751B1 (en) 2013-07-24
IL145996A (en) 2008-07-08
US20030045724A1 (en) 2003-03-06
IL145996A0 (en) 2002-07-25
US20090163553A1 (en) 2009-06-25
MXPA01012642A (es) 2002-07-22
US20080132547A1 (en) 2008-06-05
DK1977751T3 (da) 2013-09-02
CN1355798A (zh) 2002-06-26

Similar Documents

Publication Publication Date Title
BE2014C017I2 (tr)
BE2012C036I2 (tr)
JP2002513255A5 (tr)
JP2002509768A5 (tr)
JP2002516704A5 (tr)
JP2002520689A5 (tr)
JP2002517853A5 (tr)
JP2002512493A5 (tr)
JP2002510150A5 (tr)
JP2002525687A5 (tr)
JP2002524298A5 (tr)
JP2002514478A5 (tr)
JP2002522942A5 (tr)
JP2002503033A5 (tr)
JP2002515585A5 (tr)
JP2002502929A5 (tr)
JP2002537917A5 (tr)
HU0004498D0 (tr)
JP2002534291A5 (tr)
JP2002524362A5 (tr)
JP2002520787A5 (tr)
JP2002515702A5 (tr)
JP2000285185A5 (tr)
JP2002533926A5 (tr)
ECSDI990582S (tr)